The receptor-binding affinity was assessed in human prostate cells, PC-3 (GRPr-positive) and LNCaP (PSMA positive), and the tumor targeting efficacy was determined in severe combined immunodeficiency (SCID) mice using DUPA-6-Ahx-(64Cu-NODAGA)-5-Ava-BBN(7-14)NH2. This evidence concerns the gene GRPR and neoplasm.